Download PDF
Exp Clin Endocrinol Diabetes 2003; 111(7): 405-414
DOI: 10.1055/s-2003-44287
Review

J. A. Barth Verlag in Georg Thieme Verlag Stuttgart · New York

Risk of Hypoglycaemia with Oral Antidiabetic Agents in Patients with Type 2 Diabetes

A. Holstein 1 , E.-H. Egberts 1
  • 11st Department of Medicine, Klinikum Lippe-Detmold, Detmold, Germany
Further Information

Publication History

Received: April 19, 2002 First decision: September 9, 2002

Accepted: March 3, 3003

Publication Date:
13 November 2003 (online)

Also available at
    Permissions and Reprints

Abstract

In patients with Type 2 diabetes, the appropriate intensity of glucose control is determined by age, life expectancy, and the presence of concomitant disease. Geriatric patients are especially susceptible to hypoglycaemia and therefore particular care should be taken in this group characterized by polypharmacy, renal or hepatic dysfunction, cardiovascular multimorbidity and malnutrition. As hypoglycaemia is a significant cause of morbidity and mortality, treatment regimens for diabetes should minimize the occurrence of hypoglycaemic episodes and be tailored to the patient's individual needs. The pharmacological options for treating Type 2 diabetes have increased considerably and the risk of hypoglycaemia of the currently available drugs varies considerably. Metformin, thiazolidinediones, and acarbose, oral antidiabetic drugs that decrease insulin resistance or postprandial glucose absorption, are associated with a low risk of hypoglycaemia. These drugs can also be used effectively in various combination regimens; however, by improving insulin sensitivity, combinations of metformin and thiolidinediones with sulphonylureas or meglitinides may considerably increase the risk of hypoglycaemia. On account of its complex pharmacoprofile glibenclamide is a problematic substance carrying a high risk of hypoglycaemia. There are limited preliminary data indicating that, under routine conditions, glimepiride may be associated with a lower risk of hypoglycaemia than glibenclamide and is no more likely to cause hypoglycaemia than other shorter-acting agents such as gliclazide and glipizide. Nateglinide and repaglinide as short-acting insulin secretagogues may be associated with a reduced risk of hypoglycaemia compared with glibenclamide, in particular when dosed flexibly. Repaglinide might be beneficial in individuals with renal impairment.

Key words

Hypoglycaemia - Type 2 diabetes - sulphonylureas - glibenclamide - glimepiride - meglitinides - thiazolidinediones - metformin - acarbose

References

  • 1 Aronoff S, Rosenblatt S, Braithwaite S, Egan J, Mathisen A L, Schneider R L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with Type 2 diabetes.  Diabetes Care. 2000;  23 1605-1611
    CrossrefPubMedGoogle Scholar
  • 2 Asplund K, Wiholm B E, Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases.  Diabetologia. 1983;  24 412-417
    PubMedGoogle Scholar
  • 3 Bachmann W, Löbe A, Lacher F. Medikamentös bedingte Hypoglykämien bei Typ-II-Diabetes.  Diabetes und Stoffwechsel. 1995;  4 83-89
    PubMedGoogle Scholar
  • 4 Badian M, Korn A, Lehr K-H, Malerczyk V, Waldhausl W. Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration.  Drug Metab Drug Interact. 1996;  13 69-85
    PubMedGoogle Scholar
  • 5 Balant L, Zahnd G, Gorgia A, Schwarz R, Fabre J. Pharmacokinetics of glipizide in man: influence of renal insufficiency.  Diabetologia. 1973;  9 (Suppl) 331-338
    CrossrefPubMedGoogle Scholar
  • 6 Balant L, Zahnd G R, Weber F, Fabre J. Behaviour of glibenclamide on repeated administration to diabetic patients.  Eur J Clin Pharmacol. 1977;  11 19-25
    CrossrefPubMedGoogle Scholar
  • 7 Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y. Glibenclamide-induced hypoglycemic coma in 51 older patients with type 2 diabetes mellitus.  JAGS. 1999;  47 631-633
    PubMedGoogle Scholar
  • 8 Burge M R, Zeise T M, Sohby T A, Rassam A G, Schade D S. Low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulfonylurea-induced low blood glucose.  Diabetes Care. 1999;  22 2037-2043
    PubMedGoogle Scholar
  • 9 Campbell D, Gordon B, Ings R, Beaufils M, Meyrier A, Jones R. The effects of renal disease on the pharmacokinetics of gliclazide in diabetic patients.  Br J Clin Pharmacol. 1985;  21 P572-573
    PubMedGoogle Scholar
  • 10 Clark C M, Goldberg R B. Postgraduate medicine special report: therapeutic strategies for managing NIDDM. Whitehouse F, Gavin J Therapeutic Strategies for Managing NIDDM. McGraw-Hill Healthcare Information Group 1997: 45-56
    Google Scholar
  • 11 Corsonello A, Pedone C, Corica F, Malara A, Carosella L, Sgadari A, Mauro V N, Ceruso D, Pahor M, Carbonin P. Antihypertensive drug therapy and hypoglycemia in elderly diabetic patients treated with insulin and/or sulfonylureas. Gruppo Italiano di Farmacovigilanza nell'Anziano (GIFA).  Eur J Epidemiol. 1999;  15 893-901
    CrossrefPubMedGoogle Scholar
  • 12 Cryer P E. Hypoglycaemia: The limiting factor in the glycaemic management of type I and type II diabetes.  Diabetologia. 2002;  45 937-948
    CrossrefPubMedGoogle Scholar
  • 13 Damsbo P, Clauson P, Marbury T C, Windfeld K. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.  Diabetes Care. 1999;  22 789-794
    PubMedGoogle Scholar
  • 14 Davidson M B, Peters A L. An overview of metformin in the treatment of type 2 diabetes mellitus.  Am J Med. 1997;  102 99-110
    CrossrefPubMedGoogle Scholar
  • 15 DCCT . Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial: Diabetes Control and Complications Trial Research Group.  Am J Med. 1991;  90 450-459
    PubMedGoogle Scholar
  • 16 DCCT . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  New Eng J Med. 1993;  329 977-986
    PubMedGoogle Scholar
  • 17 Di Cicco R A, Allen A, Carr A, Fowles S, Jorkasky D K, Freed M I. Rosiglitazone does not alter the pharmacokinetics of metformin.  J Clin Pharmacol. 2000;  40 1280-1285
    PubMedGoogle Scholar
  • 18 Dills D, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group.  Horm Metab Res. 1996;  28 426-429
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Dreary I J. Symptoms of hypoglycaemia and effects on mental performance and emotions. Frier B, Fisher B Hypoglycaemia in Clinical Diabetes. Chichester; Wiley 1999: 29-54
    Google Scholar
  • 20 Einhorn D, Rendell M, Rosenzweig J, Egan J, Mathisen A, Schneider R. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controled study.  Clinical Therapeutics. 2000 a;  22 1395-1409
    CrossrefPubMedGoogle Scholar
  • 21 Einhorn D, Rendell M, Rosenzweig J, Egan J W, Mathisen A L, Schneider R L. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.  Clin Ther. 2000 b;  22 1395-1409
    CrossrefPubMedGoogle Scholar
  • 22 Fisher B M, Heller S. Mortality, cardiovascular morbidity, and possible effects of hypoglycaemia on diabetic complications. Frier BM, Fisher BM Hypoglycaemia in Clinical Diabetes. Chichester; Wiley 1999: 77-82
    Google Scholar
  • 23 Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus.  JAMA. 2000;  283 1695-1702
    CrossrefPubMedGoogle Scholar
  • 24 Frier B M, Fisher M. Impaired hypoglycaemia awareness. Frier BM, Fisher BM Hypoglycaemia in Clinical Diabetes. Chichester; Wiley 1999: 111-146
    Google Scholar
  • 25 Gudat U, Heinemann L. The effect of physical exercise on glycemia on healthy subjects following administration of glimepiride.  Arzneimittelforsch. 1996;  46 606-609
    PubMedGoogle Scholar
  • 26 Hanefeld M, Bouter K P, Dickinson S, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.  Diabetes Care. 2000;  23 202-207
    CrossrefPubMedGoogle Scholar
  • 27 Hansen A M, Christensen I T, Hansen J B, Carr R D, Ashcroft F M, Wahl P. Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.  Diabetes. 2002;  51 2789-2795
    PubMedGoogle Scholar
  • 28 Harrigan R A, Nathan M S, Beattie P. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.  Ann Emerg Med. 2001;  38 68-78
    PubMedGoogle Scholar
  • 29 Harrower A D. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas.  J Diabetes Complicat. 1994;  8 201-203
    PubMedGoogle Scholar
  • 30 Harrower A D. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency.  Clin Pharmacokinet. 1996;  31 111-119
    CrossrefPubMedGoogle Scholar
  • 31 Hart S, Frier B. Causes, management, and morbidity of acute hypoglycaemia in adults requiring hospital admission.  QJM. 1998;  91 505-510
    PubMedGoogle Scholar
  • 32 Hasslacher C, Koselj M, Gall M, Sieber J, Leyck Dieken M. Safety and efficacy of repaglinide in 281 type 2 diabetic patients with or without renal impairment.  Diabetes. 2001;  50 (Suppl 2) A116
    PubMedGoogle Scholar
  • 33 Hatorp V, Walther K H, Christensen M S, Haug-Pihale G. Single-dose pharmacokinetics of repaglinide in subjects with chronic liver disease.  J Clin Pharmacol. 2000;  40 142-152
    CrossrefPubMedGoogle Scholar
  • 34 Hellman B, Sehlin J, Taljedal I B. Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in beta-cell-rich pancreatic islets.  Acta Endocrinol (Copenh). 1984;  105 385-390
    PubMedGoogle Scholar
  • 35 Hollander P A, Schwartz S L, Gatlin M R, Haas S J, Zheng H, Foley J E, Dunning B E. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.  Diabetes Care. 2001;  24 983-988
    PubMedGoogle Scholar
  • 36 Holman R R, Cull C A, Turner R C. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UKPDS 44).  Diabetes Care. 1999;  22 960-964
    CrossrefPubMedGoogle Scholar
  • 37 Holstein A, Plaschke A, Egberts E-H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide.  Diabetes Metab Res Rev. 2001;  17 467-473
    CrossrefPubMedGoogle Scholar
  • 38 Holstein A, Plaschke A, Egberts E-H. Incidence and costs of severe hypoglycemia.  Diabetes Care. 2002;  25 2109-2110
    CrossrefPubMedGoogle Scholar
  • 39 Holstein A, Plaschke A, Egberts E-H. Risk factors for prolonged and non-prolonged hypoglycemia in sulfonylurea-treated patients.  Diabetes. 2002 a;  51 (Suppl 2) A491-492
    PubMedGoogle Scholar
  • 40 Horton E S, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.  Diabetes Care. 2000;  23 1660-1665
    CrossrefPubMedGoogle Scholar
  • 41 Jaap A J, Jones G C, Mc Crimmon R J, Deary I J, Frier B M. Perceived symptoms of hypoglycaemia in elderly type 2 diabetic patients treated with insulin.  Diabet Med. 1998;  15 398-401
    CrossrefPubMedGoogle Scholar
  • 42 Jonsson A, Rydberg T, Sterner G, Melander A. Pharmacokinetics of glibenclamide and ist metabolites in diabetic patients with impaired renal function.  Eur J Clin Pharmacol. 1998;  53 429-435
    CrossrefPubMedGoogle Scholar
  • 43 Karam J H, Sanz N, Salamon E, Nolte M S. Selective unresponsiveness of pancreatic B cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM.  Diabetes. 1986;  35 1314-1320
    PubMedGoogle Scholar
  • 44 Kemmer F W, Tacken M, Berger M. Mechanism of exercise-induced hypoglycemia during sulfonylurea treatment.  Diabetes. 1987;  36 1178-1182
    CrossrefPubMedGoogle Scholar
  • 45 Kerr D, Macdonald I A, Heller S R, Tattersall R B. Alcohol causes hypoglycaemic unawareness in healthy volunteers and patients with type I (insulin-dependent) diabetes.  Diabetologia. 1990;  33 216-221
    CrossrefPubMedGoogle Scholar
  • 46 Kipnes M, Krosnick A, Rendell M S, Egan J W, Mathisen A L, Schneider R L. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.  Am J Med. 2001;  111 10-17
    PubMedGoogle Scholar
  • 47 Kramer W, Muller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes.  Horm Metab Res. 1996;  28 469-487
    PubMedGoogle Scholar
  • 48 Krepinsky J, Ingram A J, Clase C M. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease.  Am J Kidney Dis. 2000;  35 500-505
    PubMedGoogle Scholar
  • 49 Landgraf R, Bilo H J, Muller P G. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.  Eur J Clin Pharmacol. 1999;  55 165-171
    CrossrefPubMedGoogle Scholar
  • 50 Landstedt-Hallin L, Adamson U, Lins P E. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes.  J Clin Endocrinol Metab. 1999;  84 3140-3145
    CrossrefPubMedGoogle Scholar
  • 51 Lebovitz H E, Melander A. Sulfonylureas basic aspects and clinical uses. Alberti KGMM, DeFronzo RA, Keen H, Zimmet P International Textbook of Diabetes Mellitus. Vol. 1. Chichester; Wiley 1992: 745-772
    Google Scholar
  • 52 Levy C J, Kinsley B T, Bjaj M, Simonson D C. Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM.  Diabetes Care. 1998;  21 1330-1338
    CrossrefPubMedGoogle Scholar
  • 53 Lindblad U, Melander A. Sulphonylurea dose-response relationships: relation to clinical practice.  Diabetes Obes Metab. 2000;  2 25-31
    PubMedGoogle Scholar
  • 54 Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard A. Comparison between repaglinide and glipizide in type 2 diabetes mellitus: a 1-year multicentre study.  Diabet Med. 2001;  18 395-401
    CrossrefPubMedGoogle Scholar
  • 55 Mafauzy M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting.  Diabetes Res Clin Pract. 2002;  58 45-53
    CrossrefPubMedGoogle Scholar
  • 56 Marbury T, Huang W C, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial.  Diab Res Clin Pract. 1999;  43 155-166
    CrossrefPubMedGoogle Scholar
  • 57 Marbury T, Ruckle J L, Hartop V, Andersen M P, Kramer Nielsen K, Huang W C, Strange P. Pharmocokinetics of repaglinide in subjects with renal impairment.  Clin Pharmacol Therap. 2000;  67 7-15
    PubMedGoogle Scholar
  • 58 Massi-Benedetti M, Herz M, Pfeiffer C. The effects of acute exercise on metabolic control in type 2 diabetic patients treated with glimepiride orglibenclamide.  Horm Metab Res. 1996;  28 451-455
    PubMedGoogle Scholar
  • 59 Miller C D, Phillips L S, Ziemer D C, Gallina D L, Cook C B, El-Kebbi I M. Hypoglycemia in patients with type 2 diabetes mellitus.  Arch Intern Med. 2001;  161 1653-1659
    PubMedGoogle Scholar
  • 60 Mooradian A D, Kalis J, Nugent C A. The nutritional status of ambulatory elderly type 2 diabetic patients.  Age. 1990;  13 87-89
    PubMedGoogle Scholar
  • 61 Morley J E. The elderly type 2 diabetic patient: special considerations.  Diabet Med. 1998;  15 (Suppl 4) S41-46
    CrossrefPubMedGoogle Scholar
  • 62 Morris A D, Boyle D I, McMahon A D, Pearce H, Evans J M, Newton R W, Jung R T, MacDonald T M. ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside, Scotland. Medicines Monitoring Unit.  Diabetes Care. 1997;  20 1363-1367
    PubMedGoogle Scholar
  • 63 Mueller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes.  Horm Metab Res. 1996;  28 469-487
    PubMedGoogle Scholar
  • 64 Mueller G, Hartz D, Punter J, Okonomopolos R, Kramer W. Differential interaction of glimepiride and glibenclamide with the beta cell sulphonylurea receptor. I. Binding characteristics.  Biochim Biophys Acta. 1994;  1191 267-277
    PubMedGoogle Scholar
  • 65 Niemi M, Brackman J T, Neuvonen M, Laitila J, Neuvonen P J, Kivisto K T. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.  Clin Pharmacol Ther. 2001;  69 194-200
    CrossrefPubMedGoogle Scholar
  • 66 Niemi M, Neuvonen P J, Kivisto K T. Effects of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride.  Clin Pharmacol Ther. 2001 a;  70 439-445
    PubMedGoogle Scholar
  • 67 Niemi M, Cascorbi I, Timm R, Kroemer H K, Neuvonen P J, Kivisto K T. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.  Clin Pharmacol Ther. 2002;  72 326-332
    CrossrefPubMedGoogle Scholar
  • 68 Nolan J J, Jones N P, Patwardhan R, Deacon L F. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus.  Diabet Med. 2000;  17 287-294
    CrossrefPubMedGoogle Scholar
  • 69 Pearson J G, Antal E J, Raehl C L, Gorsch H K, Craig W A, Albert K S, Welling P G. Pharmacokinetic disposition of 14 C - glyburide in patients with varying renal function.  Clin Pharmacol Ther. 1986;  39 318-324
    PubMedGoogle Scholar
  • 70 Roberge R J, Kaplan R, Frank R, Fore C. Glyburide-ciprofloxacin interaction with resistant hypoglycemia.  Ann Emerg Med. 2000;  36 160-163
    PubMedGoogle Scholar
  • 71 Rosenblatt S, Miskin B, Glazer N B, Prince M J, Robertson K E. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.  Coron Artery Dis. 2001;  12 413-423
    CrossrefPubMedGoogle Scholar
  • 72 Rosenkranz B. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.  Horm Metab Res. 1996;  28 434-439
    PubMedGoogle Scholar
  • 73 Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment.  Diabetologia. 1996;  39 1617-1624
    CrossrefPubMedGoogle Scholar
  • 74 Rosenstock J, Shen S G, Gatlin M R, Foley J E. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes.  Diabetes Care. 2002;  25 1529-1533
    PubMedGoogle Scholar
  • 75 Rydberg T, Wahlin-Boll E, Melander A. Determination of glibenclamide and its two major metabolites in human serum and urine by column liquid chromatography.  J Chromatogr. 1991;  564 223-233
    PubMedGoogle Scholar
  • 76 Rydberg T, Jonsson A, Roder M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans.  Diabetes Care. 1994;  17 1026-1030
    PubMedGoogle Scholar
  • 77 Sawicki P, Düwel P, Berger M. Struktur der Notfallversorgung schwerer Hypoglykämien.  Diabetes und Stoffwechsel. 1994;  3 176
    PubMedGoogle Scholar
  • 78 Segel S A, Paramore D S, Cryer P E. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes.  Diabetes. 2002;  51 724-733
    CrossrefPubMedGoogle Scholar
  • 79 Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.  Diabetes Care. 2000;  23 (Suppl 2) B21-29
    PubMedGoogle Scholar
  • 80 Shorr R I, Ray W A, Daugherty J R, Griffin M R. Individual sulfonylureas and serious hypoglycemia in older people.  JAGS. 1997;  44 751-755
    PubMedGoogle Scholar
  • 81 Sills M N, Ogu C C, Maxa J. Prolonged hypoglycemic crisis associated with glyburide.  Pharmacotherapy. 1997;  17 1338-1340
    PubMedGoogle Scholar
  • 82 Song D K, Ashcroft F M. Glimepiride block of cloned beta-cell, cardiac, and smooth muscle K(ATP) channels.  Br J Pharmacol. 2001;  133 193-199
    CrossrefPubMedGoogle Scholar
  • 83 Sonnenberg G, Garg D C, Weidler D, Dixon R, Jaber L, Bowen A, DeCherney G, Mullican W, Stonesifer L. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin dependent diabetes mellitus.  Ann Pharmacother. 1997;  31 671-676
    PubMedGoogle Scholar
  • 84 Sonnenblick M, Shilo S. Glibenclamide induced prolonged hypoglycaemia.  Age Ageing. 1986;  15 185-189
    PubMedGoogle Scholar
  • 85 Spranger R, Bachmann W. Hypoglykämische Stoffwechselentgleisungen bei medikamentös behandelten Typ-II-Diabetikern.  Diabetes und Stoffwechsel. 1999;  8 (Suppl 1) 89
    PubMedGoogle Scholar
  • 86 Stahl M, Berger W. Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas.  Diabet Med. 1999;  16 586-590
    CrossrefPubMedGoogle Scholar
  • 87 Stumvoll M, Häring H U. Glitazones. Clinical effects and molecular mechanisms.  Ann Med. 2002;  34 217-224
    PubMedGoogle Scholar
  • 88 Sugarman J R. Hypoglycemia-associated hospitalizations in a population with a high prevalence of non-insulin-dependent diabetes mellitus.  Diabetes Res Clin Pract. 1991;  14 139-147
    CrossrefPubMedGoogle Scholar
  • 89 Tatterhall R B. Frequency, causes, and treatment of hypoglycaemia. Frier B, Fisher B Hypoglycaemia in Clinical Diabetes. Chichester; Wiley 1999: 55-89
    Google Scholar
  • 90 Tessier D, Dawson K, Tetrault J P, Bravo G, Meneilly G S. Glibenclamide vs. gliclazide in type 2 diabetes of the elderly.  Diabet Med. 1994;  11 974-980
    PubMedGoogle Scholar
  • 91 ter Braak E W, Appelmann A M, van Der Tweel I, Erkelens D W, van Haeften T W. The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycemia.  Diabetes Care. 2002;  25 107-112
    PubMedGoogle Scholar
  • 92 UKPDS28 . A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U. K. Prospective Diabetes Study Group.  Diabetes Care. 1998;  21 87-92
    PubMedGoogle Scholar
  • 93 UKPDS33 . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33).  Lancet. 1998;  352 837-853
    CrossrefPubMedGoogle Scholar
  • 94 van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas.  J Clin Epidemiol. 1997;  50 735-741
    CrossrefPubMedGoogle Scholar
  • 95 Veneman T, Mitrakou A, McKan M, Cryer P, Gerich J. Induction of hypoglycaemia unawareness by asymptomatic nocturnal hypoglycaemia.  Diabetes. 1993;  42 1233-1237
    CrossrefPubMedGoogle Scholar
  • 96 Veneman T F, Erkelens D W. Clinical review 88: Hypoglycemia unawareness in noninsulin-dependent diabetes mellitus.  J Clin Endocrinol Metab. 1997;  82 1682 -1684
    CrossrefPubMedGoogle Scholar
  • 97 Werner A L, Travaglini M T. A review of rosiglitazone in type 2 diabetes mellitus.  Pharmacotherapy. 2001;  21 1082-1099
    CrossrefPubMedGoogle Scholar
  • 98 Whipple A O. The surgical therapy of hyperinsulinism.  J Int Chir. 1938;  3 237-276
    PubMedGoogle Scholar
  • 99 Wolffenbuttel B H, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.  Diabetes Care. 1999;  22 463-467
    CrossrefPubMedGoogle Scholar
  • 100 Wolffenbuttel B H, Gomist R, Squatrito S, Jones N P, Patwardhan R N. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients.  Diabet Med. 2000;  17 40-47
    CrossrefPubMedGoogle Scholar
  • 101 Yee H S, Fong N T. A review of the safety and efficacy of acarbose in diabetes mellitus.  Pharmacotherapy. 1996;  16 792-805
    PubMedGoogle Scholar

Dr. med. Andreas Holstein

1st Department of Medicine
Klinikum Lippe-Detmold

Röntgenstraße 18

32756 Detmold

Germany

Phone: + 495231721171

Fax: + 49 52 31 72 10 35

Email: Andreas.Holstein@t-online.de

      >